Publication

What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

van der Geest, K. S. M., Sandovici, M., van Sleen, Y., Sanders, J-S., Bos, N. A., Abdulahad, W. H., Stegeman, C. A., Heeringa, P., Rutgers, A., Kallenberg, C. G. M., Boots, A. M. H. & Brouwer, E., Sep-2018, In : Arthritis & Rheumatology. 70, 9, p. 1366-1376 11 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.

Original languageEnglish
Pages (from-to)1366-1376
Number of pages11
JournalArthritis & Rheumatology
Volume70
Issue number9
Publication statusPublished - Sep-2018

    Keywords

  • PLACEBO-CONTROLLED TRIAL, POPULATION-BASED COHORT, VARICELLA-ZOSTER-VIRUS, ERYTHROCYTE SEDIMENTATION-RATE, UNINFLAMED TEMPORAL ARTERY, ENDOTHELIAL GROWTH-FACTOR, LARGE-VESSEL VASCULITIS, PERMANENT VISUAL-LOSS, POLYMYALGIA-RHEUMATICA, ISCHEMIC COMPLICATIONS

View graph of relations

Download statistics

No data available

ID: 56832234